Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 17, 2018 - Issue 4
Submit an article Journal homepage
292
Views
14
CrossRef citations to date
0
Altmetric
Drug Safety Evaluation

Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab

Mario CazzolaUnit of Respiratory Medicine, Department of Experimental Medicine and Surgery, University of Rome ‘Tor Vergata’, Rome, ItalyCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-4895-9707View further author information
ORCID Icon,
Maria Gabriella MateraUnit of Pharmacology, Department of Experimental Medicine, University of Campania ‘Luigi Vanvitelli’, Naples, ItalyView further author information
,
Francesca Levi-SchafferPharmacology and Experimental Therapeutics Unit, School of Pharmacy, Institute for Drug Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, IsraelView further author information
&
Paola RoglianiUnit of Respiratory Medicine, Department of Experimental Medicine and Surgery, University of Rome ‘Tor Vergata’, Rome, ItalyView further author information
Pages 429-435 | Received 10 Jan 2018, Accepted 27 Feb 2018, Published online: 08 Mar 2018

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Francesco Menzella, Matteo Fontana, Patrizia Ruggiero, Francesco Livrieri & Nicola Facciolongo. (2022) Home-based treatment of biologics for asthma: who, what, where, when and why. Expert Review of Respiratory Medicine 16:4, pages 419-428.
Read now
Federica Porcaro, Renato Cutrera & Giovanni Battista Pajno. (2019) Options of immunotherapeutic treatments for children with asthma. Expert Review of Respiratory Medicine 13:10, pages 937-949.
Read now
Shiven S. Patel, Thomas B. Casale & Juan Carlos Cardet. (2018) Biological therapies for eosinophilic asthma. Expert Opinion on Biological Therapy 18:7, pages 747-754.
Read now

Articles from other publishers (11)

David Z. Allen & Amber U. Luong. (2023) Reserve Biologics for Chronic Rhinosinusitis with Nasal Polyps After Failed Sinus Surgery. Current Otorhinolaryngology Reports.
Crossref
Bruce L. Zuraw, Marcus Maurer, Daniel J. Sexton & Marco Cicardi. (2023) Therapeutic monoclonal antibodies with a focus on hereditary angioedema. Allergology International 72:1, pages 54-62.
Crossref
Maria Gabriella Matera, Paola Rogliani, Andrea Bianco & Mario Cazzola. 2022. Lung Diseases and Cancer. Lung Diseases and Cancer 265 280 .
Francesco Menzella, Andrea Ballarin, Maria Sartor, Ariel Fabian Floriani, Lorenzo Corsi, Cristina Dartora, Silvia Tonin & Micaela Romagnoli. (2022) Comparison between clinical trials and real-world evidence studies on biologics for severe asthma. Journal of International Medical Research 50:11, pages 030006052211336.
Crossref
Bernard S. Buetow, Gregg D Cappon, Laura M. Aschenbrenner, Lawrence Updyke, Vince R. Torti, Mark Evans, Shana R. Dalton, Steven Bailey & Christopher J. Bowman. (2022) Regulatory Experience Assessing the Carcinogenic Potential of a Monoclonal Antibody Inhibiting PCSK9, Bococizumab, Including a 2-Year Carcinogenicity Study in Rats. International Journal of Toxicology 41:5, pages 389-401.
Crossref
Sainan Bian, Pingping Zhang, Lisha Li, Zixi Wang, Le Cui, Yingyang Xu, Kai Guan, Bin Zhao & Zhuanggui Chen. (2021) Anaphylaxis Associated With Allergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World Study Based on the US Food and Drug Administration Adverse Event Reporting System. Frontiers in Pharmacology 12.
Crossref
Lisha Li, Zixi Wang, Le Cui, Yingyang Xu, Kai Guan & Bin Zhao. (2021) Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab. Clinical and Translational Allergy 11:4.
Crossref
Askin Gülsen, Bettina Wedi & Uta Jappe. (2020) Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches. Allergo Journal International 29:5, pages 139-154.
Crossref
Askin Gülsen, Bettina Wedi & Uta Jappe. (2020) Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches*. Allergo Journal 29:5, pages 25-41.
Crossref
Maria Gabriella Matera, Luigino Calzetta, Paola Rogliani & Mario Cazzola. (2019) Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. Respiratory Medicine 153, pages 3-13.
Crossref
R. S. Fassakhov. (2018) Severe eosinophilic asthma: therapeutic potential of Reslizumab. Medical Council:15, pages 70-75.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.